Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
or

Crispr Therapeutics Ag (CRSP)

Crispr Therapeutics Ag (CRSP)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
52.22 +2.50 (+5.03%) 02/18/25 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 52.43 +0.21 (+0.40%) 19:57 ET
Quote Overview for Tue, Feb 18th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
51.02
Day High
55.30
Open 52.24
Previous Close 49.72 49.72
Volume 6,027,100 6,027,100
Avg Vol 2,648,330 2,648,330
Stochastic %K 80.56% 80.56%
Weighted Alpha -30.93 -30.93
5-Day Change +12.81 (+32.50%) +12.81 (+32.50%)
52-Week Range 36.52 - 91.10 36.52 - 91.10
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,264,684
  • Shares Outstanding, K 85,774
  • Annual Sales, $ 371,210 K
  • Annual Income, $ -153,610 K
  • EBIT $ -332 M
  • EBITDA $ -313 M
  • 60-Month Beta 1.67
  • Price/Sales 99.97
  • Price/Cash Flow N/A
  • Price/Book 1.92

Options Overview Details

View History
  • Implied Volatility 60.55% ( -0.31%)
  • Historical Volatility 60.74%
  • IV Percentile 63%
  • IV Rank 43.90%
  • IV High 79.75% on 10/30/24
  • IV Low 45.53% on 08/26/24
  • Put/Call Vol Ratio 0.27
  • Today's Volume 25,929
  • Volume Avg (30-Day) 11,633
  • Put/Call OI Ratio 0.47
  • Today's Open Interest 90,732
  • Open Int (30-Day) 77,648

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 29 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -1.30
  • Number of Estimates 11
  • High Estimate -0.74
  • Low Estimate -1.74
  • Prior Year -1.43
  • Growth Rate Est. (year over year) +9.09%

Price Performance

See More
Period Period Low Period High Performance
1-Month
38.28 +36.42%
on 02/11/25
Period Open: 40.53
55.30 -5.57%
on 02/18/25
+11.69 (+28.84%)
since 01/17/25
3-Month
36.52 +42.99%
on 01/13/25
Period Open: 47.30
55.50 -5.91%
on 12/02/24
+4.92 (+10.40%)
since 11/18/24
52-Week
36.52 +42.99%
on 01/13/25
Period Open: 82.22
91.10 -42.68%
on 02/22/24
-30.00 (-36.49%)
since 02/16/24

Most Recent Stories

More News
The Ultimate Healthcare Stock to Buy With $500 Right Now

Healthcare isn't the hottest sector these days. While the S&P 500 has soared nearly 21% over the last 12 months, healthcare stocks as a group are barely in positive territory.

CRSP : 52.22 (+5.03%)
VRTX : 462.11 (+0.68%)
Why CRISPR Therapeutics Stock Was a Massive Winner on Wednesday

On Hump Day, investors piled into CRISPR Therapeutics (NASDAQ: CRSP) stock, sending its price more than 9% higher at the trading session's close. They were highly encouraged by the specialized healthcare...

CRSP : 52.22 (+5.03%)
VRTX : 462.11 (+0.68%)
Investing $1,000 in These 3 Beaten-Down Stocks Could Be a Brilliant Move

Investing in stocks that aren't performing well can be a good move, but only if there are good reasons to think they will recover. That isn't the case for many companies that have lagged broader equities....

CRSP : 52.22 (+5.03%)
REGN : 680.00 (+0.95%)
AMGN : 292.80 (+0.56%)
Is Vertex Pharmaceuticals a Buy Now That the FDA Approved Its New Pain Drug?

Lately, one of America's leading pharmaceutical companies can't catch a break from Wall Street. Shares of Vertex Pharmaceuticals (NASDAQ: VRTX) are down about 9% from a peak the stock set in November,...

CRSP : 52.22 (+5.03%)
VRTX : 462.11 (+0.68%)
MaxCyte: Building the Future of Cell and Gene Therapy Innovation

MaxCyte's proprietary Flow Electroporation technology enables companies like Vertex and CRISPR Therapeutics to get FDA approved for their gene-editing therapy.

CRSP : 52.22 (+5.03%)
MXCT : 4.02 (-3.60%)
VRTX : 462.11 (+0.68%)
My Top 5 Stocks to Buy in Early 2025

It's the start of a new year, and that makes now the perfect time to load up on stocks that could boost your portfolio in 2025 and over the long term. The healthcare space is a great place to look for...

ABT : 130.18 (-0.33%)
CRSP : 52.22 (+5.03%)
LLY : 857.20 (+1.53%)
ISRG : 600.89 (+0.90%)
PFE : 25.56 (+0.12%)
3 Unstoppable Stocks to Buy in 2025

You can look at the momentum for some stocks and have a feeling that it's about to end. Others, though, have such strong underlying business prospects that they're practically unstoppable.

CRSP : 52.22 (+5.03%)
VRTX : 462.11 (+0.68%)
LLY : 857.20 (+1.53%)
ISRG : 600.89 (+0.90%)
2 Magnificent Stocks to Buy That Are Near Their 52-Week Lows

Some investors believe you make money when you buy a stock, not when you sell it. The logic behind this idea is that investing in the right stock at the right time -- and holding onto it for a while --...

CRSP : 52.22 (+5.03%)
AMGN : 292.80 (+0.56%)
Vertex's Pain Drug: Big Pharma's Next Major Success?

Vertex Pharmaceuticals' innovative pain drug holds significant potential, positioning the company for substantial growth in the expanding market.

CRSP : 52.22 (+5.03%)
VRTX : 462.11 (+0.68%)
My 10 Top Stocks to Buy to Start the New Year Off Right

Investors scored big wins last year as the S&P 500, the Nasdaq , and the Dow Jones Industrial Average all climbed by double digits. Investor enthusiasm about technology and growth stocks, and the economic...

NVDA : 139.40 (+0.40%)
META : 716.37 (-2.76%)
CRSP : 52.22 (+5.03%)
CRWD : 455.36 (+0.80%)
LLY : 857.20 (+1.53%)
CHWY : 38.06 (+1.01%)
GS : 672.19 (+1.76%)
SPY : 611.49 (+0.29%)
ISRG : 600.89 (+0.90%)
AMZN : 226.65 (-0.89%)
CRM : 328.96 (+0.74%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

CRISPR Therapeutics AG is a leading gene editing company focused on developing CRISPR/Cas9-based therapeutics. The company is rapidly leveraging its CRISPR/Cas9 gene-editing platform to make therapies for the treatment of hemoglobinopathies, cancer, diabetes and other diseases.

See More

Key Turning Points

3rd Resistance Point 58.95
2nd Resistance Point 57.13
1st Resistance Point 54.67
Last Price 52.22
1st Support Level 50.39
2nd Support Level 48.57
3rd Support Level 46.11

See More

52-Week High 91.10
Fibonacci 61.8% 70.25
Fibonacci 50% 63.81
Fibonacci 38.2% 57.37
Last Price 52.22
52-Week Low 36.52

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

Increase Profitable Opportunities with Barchart's Technical Opinion